Last reviewed · How we verify
NCT03553446
50% Effective Concentration of Sevoflurane for Immobility
NA trial testing children receiving sevoflurane in Anesthetics, Inhalation in 23 participants. Completed in 30 April 2021.
26 March 2021
Quick facts
| Lead sponsor | Yeungnam University College of Medicine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 23 |
| Start date | 29 July 2018 |
| Primary completion | 26 March 2021 |
| Estimated completion | 30 April 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- children receiving sevoflurane — full drug profile →
Conditions studied
- Anesthetics, Inhalation — all drugs for Anesthetics, Inhalation →
Sponsor
Yeungnam University College of Medicine
Who can join
Adults 3 to 12, any sex, with Anesthetics, Inhalation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sevoflurane is as attractive inhalation agent fore deep sedation in children undergoing short invasive procedure because of lack of irritation to the respiratory tract, a pleasant odor and rapid clinical effect and recovery due to low blood gas partition coefficient. The aim of this study is to determine the optimum inspired concentration of sevoflurane required for immobility during botulinum toxin injection in spontaneously breathing children with cerebral palsy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
50% effective concentration of sevoflurane for immobility in cerebral palsy children undergoing botulinum toxin injection.
Kim K, Lee E, Jung SM, Baek J. · · 2022 · PMID 36281165 · DOI 10.1097/md.0000000000030928
Verify or expand the search:
- PubMed search for NCT03553446
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Yeungnam University College of Medicine trials
Trials by the same sponsor.
- NCT07461441 — Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal · Phase 3 · recruiting
- NCT05672979 — Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy · Phase 3 · unknown
- NCT05505123 — Sevoflurane and Propofol for Botulinum Toxin Injection · NA · withdrawn
- NCT04190082 — The Effect of Bispectral Index Monitoring on Recovery From Deep Sedation · terminated
- NCT04679337 — Renal Oxygen Saturation During Off-pump Coronary Artery Bypass Graft Surgery · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03553446 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yeungnam University College of Medicine
- Last refreshed: 23 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03553446.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing